Urval av publikationer
En stark vetenskaplig grund kring de potentiella fördelarna med arfolitixorin, har byggts upp med omfattande forskning.
Nedan följer ett urval av tillgängliga resultat:
David A. Drubin, et al. ”MYC as a candidate upstream controller involved in TYMS gene expression and 5-FU/folate treatment efficacy in colorectal cancer”
Yvonne Wettergren, et al. ”Tumoral expression of folate-associated genes is associated with progression-free survival of patients with advanced colorectal cancer”
Roger Tell, et al. “Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy”
Helena Taflin, et al. ” Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin”
Springer Link, Oktober, 2020 >>
Heinz-Josef Lenz, et al. ”An open-label Phase III study of arfolitixorin vs leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer”
Stintzing, Sebastian, et al. ”Open-label Phase III Study of Arfolitixorin vs Leucovorin in Modifi ed FOLFOX-6 for First-line Treatment of Metastatic Colorectal Cancer: AGENT”.
Poster at ESMO 2019 >>
Carlsson, Göran, et al. ”ISO-CC-005; a phase I/II study of arfolitixorin ([6R]-5,10-MTHF) in combination with 5-fluorouracil (5-FU), irinotecan and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer”.
Poster at ESMO 2018 >>
Gustavsson, Bengt, et al. ”Folate gene prediction of treatment response to 5-FU and leucovorin in metastasizing colorectal cancer”.
Poster at ASCO 2018 >>
Gustavsson, Bengt, et al. ”A review of the evolution of systemic chemotherapy in the management of colorectal cancer”.
Clinical colorectal cancer 14.1 (2015): 1-10 >>
Danenberg, Peter V., et al. ”Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action”.
Critical Reviews in Oncology/Hematology 106 (2016): 118-131 >>
Taflin, Helena, et al. ”Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages.”
Cancer chemotherapy and pharmacology 74.6 (2014): 1167-1174 >>
